{"id":2742,"date":"2019-10-07T22:38:01","date_gmt":"2019-10-07T20:38:01","guid":{"rendered":"https:\/\/idibell.cat\/?page_id=2742"},"modified":"2023-11-30T14:56:51","modified_gmt":"2023-11-30T13:56:51","slug":"inflamacio-sinovial-i-metabolisme-ossi","status":"publish","type":"page","link":"https:\/\/idibell.cat\/recerca\/area-de-medicina-translacional\/programa-de-malalties-cardiovasculars-respiratories-sistemiques-i-denvelliment-cel%c2%b7lular\/inflamacio-sinovial-i-metabolisme-ossi\/","title":{"rendered":"Inflamaci\u00f3 Sinovial i Metabolisme Ossi"},"content":{"rendered":"\n

\n\t\tInflamaci\u00f3 Sinovial i Metabolisme Ossi\n\t<\/h1>\n

\n\t\tResum\n\t<\/h3>\n\t

L’artritis \u00e9s la inflamaci\u00f3 d’una o m\u00e9s articulacions, i involucra la degradaci\u00f3 del cart\u00edlag. Els or\u00edgens d’aquesta malaltia s\u00f3n variats, i el grup de inflamaci\u00f3 sinovial i Metabolisme ossi estudia tant les causes, com els tractaments associats a aquesta afecci\u00f3 i les possibles complicacions i relacions amb altres malalties com l’osteoporosi.<\/p>\n

Paral\u00b7lelament, el grup tamb\u00e9 t\u00e9 un camp d’estudi en les malalties autoimmunes sist\u00e8miques, que inclouen una gran varietat de malalties originades per una reacci\u00f3 del propi sistema immune cap al cos del pacient.<\/p>\n

322<\/h2>\n

Publicacions<\/h2>\n\t\t\t\t\"the_horse_its_treatment_in_health_and_disease_with_a_complete_guide_to_breeding_training_and_management_1906_14585649459\"\n\t\t\t\t\tL\u00ednies estrat\u00e8giques<\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\tArteritis de c\u00e8l\u00b7lules gegants
\nArtritis infecciosa
\nArtritis psori\u00e0sica
\nArtritis reumatoide
\nEspondilitis anquilosant
\nMalalties autoimmunit\u00e0ries sist\u00e8miques
\nOsteoporosi\n\t\t\t\t\t
Publicacions seleccionades<\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\t

Herrero Morant,A; Martin Varillas,JL; Castaneda,S; Maiz,O; Sanchez,J; Ortego,N;Raya,E et al, Biologic therapy in refractory neurobehcet’s disease: a multicentre study of 41 patients and literature review<\/strong>, Rheumatology (Oxford), 2022;61(11):4427-4436, doi:10.1093\/rheumatology\/keac097<\/p>\n

Morales Ivorra,I; Narv\u00e1ez,J; G\u00f3mez Vaquero,C; Moragues,C; Nolla,JM; Narv\u00e1ez,JA; Mar\u00edn L\u00f3pez,MA, Assessment of inflammation in patients with rheumatoid arthritis using thermography and machine learning: a fast and automated technique<\/strong>., RMD Open, 2022;8(2):doi:10.1136\/rmdopen-2022-002458<\/p>\n

Morales Ivorra,I; Narvaez,J;Gomez Vaquero,C; Moragues,C; Nolla,JM; Narvaez,JA; Marin Lopez,MA, A Thermographic Disease Activity Index for remote assessment of rheumatoid arthritis<\/strong>, RMD Open, 2022; 8(2): doi:10.1136\/rmdopen-2022-002615<\/p>\n

Michelena,X; Lopez Medina,C; Erra,A; Juanola,X; Font Ugalde,P; Collantes,E; Marzo Ortega,H, Characterising the axial phenotype of psoriatic arthritis: a study comparing axial psoriatic arthritis and ankylosing spondylitis with psoriasis from the REGISPONSER registry<\/strong>, RMD Open, 2022;8(2):doi:10.1136\/rmdopen-2022-002513<\/p>\n

Llop,M; Moreno,M; Navarro Compan,V; Juanola,X; de Miguel,E; Almodovar,R; Quintana,EC et al, Sustained low disease activity measured by ASDAS slow radiographic spinal progression in axial spondyloarthritis patients treated with TNF-inhibitors: data from REGISPONSERBIO<\/strong>, Arthritis Res Ther, 2022;24(1):30-30, doi:10.1186\/s13075-021-02695-5<\/p>\n\t\t\t\t\tProjectes seleccionats<\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\t

21MAR007. Design of an integrative patients stratification approach for the systemic sclerosis management<\/strong>. Fundaci\u00f3 La Marat\u00f3 de TV3. Budget: 143583. 2021-2024. PI: Narv\u00e1ez Garc\u00eda, Javier.<\/p>\n

18ACL007. ESTUDIO DE FASE 4 ABIERTO, RANDOMIZADO CONTROLADO QUE COMPARAR LA EFICACIA DE LA INTRODUCCI\u00d3N DE ADALIMUMBAB Y EL ESCALADO DE DOSIS DE METOTREXATO EN PACIENTES CON ARTRITIS PSIRI\u00c1SICA (CONTROL)<\/strong>. Budget: 47545. 2018- . PI: Ruiz Mart\u00edn, Jos\u00e9 Miguel.<\/p>\n

21PRC004. REGISPON-3: SEGUIMIENTO DEL REGISTRO ESPA\u00d1OL DE ESPONDILOARTRITIS. ASPECTOS CL\u00cdNICOS, TERAP\u00c9UTICOS Y MOLECULARES<\/strong>. Budget: 30700. 2021- . PI: Juanola Roura, Xavier.<\/p>\n

17FIS031. Red de Investigaci\u00f3n en Inflamaci\u00f3n y Enfermedades Reum\u00e1ticas (RIER)<\/strong>. Budget: 16500. 2017-2022. PI: Narv\u00e1ez Garc\u00eda, Javier.<\/p>\n

2022-018-1. PAUTAS DE TRATAMIENTO CON UPADACITINIB, CONSECUCI\u00d3N DE LOS OBJETIVOS TERAP\u00c9UTICOS Y MANTENIMIENTO DE LA RESPUESTA EN PACIENTES CON ARTRITIS REUMATOIDE DE MODERADA A GRAVE EN LA PR\u00c1CTICA REAL (UPHOLD)<\/strong>. AbbVie Spain, S.L.U. Budget: 9100. 2021- . PI: Ruiz Mart\u00edn, Jos\u00e9 Miguel.<\/p>\n\t\t\t\t\"Francisco-Javier-Narvaez-Garcia\"\n

\n\t\tNarv\u00e1ez Garcia, Francisco Javier\n\t<\/h4>\n

\n\t\tInvestigadors principals\n\t<\/h2>\n\t\t\t\t\"Francisco-Javier-Narvaez-Garcia\"\n

\n\t\tNarv\u00e1ez Garcia, Francisco Javier\n\t<\/h4>\n

\n\t\t\n\t\tfjnarvaez@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n\t\t\t\t\"avatar-188\"\n

\n\t\tG\u00f3mez Vaquero, Carmen\n\t<\/h4>\n

\n\t\t\n\t\tcarmen.gomez@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n\t\t\t\t\"Joan-Miquel-Nolla-Sol\u00e9\"\n

\n\t\tNolla Sole, Joan Miquel\n\t<\/h4>\n

\n\t\t\n\t\tjnolla@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n\t\t\t\t\"Diego-Benavent-Nu\u00f1ez\"\n

\n\t\tBenavent Nu\u00f1ez, Diego\n\t<\/h4>\n\t\t\t\t\"Antonio-rozadilla-Sacanell\"\n

\n\t\tRozadilla Sacanell, Antonio\n\t<\/h4>\n

\n\t\t\n\t\tarozadilla@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n\t\t\t\t\"avatar-188\"\n

\n\t\tNarv\u00e1ez Garcia, Jose Antonio\n\t<\/h4>\n

\n\t\t\n\t\tjnarvaezg@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n\t\t\t\t\"Xavier-Juanola-Roura2\"\n

\n\t\tJuanola Roura, Xavier\n\t<\/h4>\n

\n\t\t\n\t\txjuanola@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n\t\t\t\t\"avatar-188\"\n

\n\t\tBerbel Arcobe, Laura \n\t<\/h4>\n

\n\t\tENLLA\u00c7OS RELACIONATS\n\t<\/h4>\n

\n\t\t\n\t\t@5Romera55\n\t\t<\/a>\n\t<\/h4>\n

\n\t\tEquip\n\t<\/h2>\n\t\t\t\t\t\t\t\t\t\t\t\tCaps de grup\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tInvestigadors\/es principals\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tInvestigadors\/es cl\u00ednics\/ques\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tSuport cient\u00edfic\t\t\t\t<\/a>\n\t\t\t\t\t\tCaps de grup\n\t\t\t\t\t\t\t\t\t\t\t